Item 8.01 Other Events

On November 19, 2012, Supernus Pharmaceuticals, Inc. (the "Company") issued a press release announcing the receipt of confirmation from the Food and Drug Administration (the "FDA") that Oxtellar XR™ has been granted three years of market exclusivity. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

On November 20, 2012, Supernus Pharmaceuticals, Inc. (the "Company") issued a press release announcing the receipt of positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in ADHD patients. A copy of this press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) The following documents are furnished as Exhibits pursuant to Item 8.01, hereof:

Exhibit 99.1 - Press Release dated November 19, 2012 of the Company regarding receipt of confirmation of marketing exclusivity from the FDA.

Exhibit 99.2 - Press Release dated November 20, 2012 of the Company regarding receipt of results from its Phase IIb study on SPN-810.

---